Sugi Predict

Sugi Predict / Compounds / SCHEMBL233018

SCHEMBL233018

SCHEMBL233018

CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR5A2 O00482 2/20 0.83
▸ NR5A1 Q13285 2/20 0.83
▸ SMN1; SMN2 Q16637 1/20 0.83
▸ ALDH1A1 P00352 1/20 0.83
▸ MAPT P10636 1/20 0.74
▸ RECQL P46063 1/20 0.66
▸ FABP3 P05413 1/20 0.66
▸ SELP P16109 1/20 0.61
▸ S1PR1 P21453 1/20 0.56
▸ ADRA1D P25100 1/20 0.56
▸ PTAFR P25105 1/20 0.56
▸ HTR1D P28221 1/20 0.56
▸ HTR2C P28335 1/20 0.56
▸ ADRA1B P35368 1/20 0.56
▸ DRD3 P35462 1/20 0.56
▸ TMEM97 Q5BJF2 1/20 0.56
▸ PRKCE Q02156 1/20 0.55
▸ PRKCQ Q04759 1/20 0.55
▸ PRKCD Q05655 1/20 0.55
▸ PRKCA P17252 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31276170 1.00 NR5A2 (0.83) NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL10498201 1.00 NR5A2 (0.83) NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL31084795 1.00 NR5A2 (0.83) NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL4182988 1.00 NR5A2 (0.83) NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL13735582 1.00 NR5A2 (0.83) NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL234615 1.00 NR5A2 (0.83) NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL23834444 1.00 NR5A2 (0.83) NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL3730490 1.00 NR5A2 (0.83) NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL25777 1.00 NR5A2 (0.83) NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL31695681 1.00 NR5A2 (0.83) NR5A2NR5A1SMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144803-A1 LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF EDEN OPHTHALMIC PTE LTD. (SG) 2026-05-28 — — US claimed
EP-4743094-A1 LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF Eden Ophthalmic Pte Ltd. (SG) 2026-05-20 — — EP claimed
EP-4695401-A1 SYNTHETIC CIRCUITS AND USES THEREOF Strand Therapeutics Inc. (US) 2026-02-18 — — EP claimed
US-20250314671-A1 Diagnostic signature BCAL Diagnostics Limited (AU) 2025-10-09 — — US claimed
EP-4627352-A1 DIAGNOSIS OF METABOLIC CHANGES OF THE LIVER BY WAY OF METABOLIC ANALYSIS OF ERYTHROCYTES BY MASS SPECTROMETRY Universitätsklinikum Jena (DE) 2025-10-08 — — EP claimed
EP-4604035-A1 INVENTORY MANAGEMENT METHOD AND SYSTEM WITH SYNCHRONIZED SHELF DEVICES AND SENSORS ACTIVATION VusionGroup Deutschland GmbH (DE) 2025-08-20 — — EP claimed
WO-2025123045-A1 PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2025-06-12 — — WO claimed
WO-2025091079-A1 DIAGNOSTIC SIGNATURE BCAL Diagnostics Limited (AU) 2025-05-08 — — WO claimed
US-12292445-B2 Methods of selecting subjects for treatment with metabolomic modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-05-06 — — US claimed
EP-4334868-B1 INVENTORY MANAGEMENT METHOD AND SYSTEM WITH SYNCHRONIZED SHELF DEVICES AND SENSORS ACTIVATION CAPTANA GMBH (DE) 2025-04-30 — — EP claimed
US-20200046744-A1 Phospholipid Compositions MACHAVERT PHARMACEUTICALS, LLC 2020-02-13 — — US claimed
US-10493086-B2 Phospholipid compositions MACHAVERT PHARMACEUTICALS LLC (US) 2019-12-03 — — US claimed
EP-3458092-A1 MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER Modernatx, Inc. (US) 2019-03-27 — — EP claimed
EP-3458083-A1 POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF Modernatx, Inc. (US) 2019-03-27 — — EP claimed
US-20180344644-A1 IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF IKARIA THERAPEUTICS LLC 2018-12-06 — — US claimed
US-20180000850-A1 PHOSPHOLIPID COMPOSITIONS MACHAVERT PHARMACEUTICALS LLC 2018-01-04 — — US claimed
WO-2017201352-A1 MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER MODERNATX, INC. (US) 2017-11-23 — — WO claimed
WO-2017201350-A1 POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF MODERNATX, INC. (US) 2017-11-23 — — WO claimed
WO-2012052539-A1 NOVEL NEUTRAL (BIO)MATERIAL CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2012-04-26 — — WO claimed
EP-2444464-A1 Novel neutral (bio)material Centre National de la Recherche Scientifique (CNRS) (FR) 2012-04-25 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10493086-B2 Phospholipid compositions PHOSPHO1, SGMS1, SGMS2 NR5A2 4657/4885NR5A1 3689/4885SMN1; SMN2 1802/4885
US-20180344644-A1 IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF SGMS2, SGMS1, LIPA NR5A2 1869/4885NR5A1 296/4885SMN1; SMN2 2605/4885
US-20200046744-A1 Phospholipid Compositions PHOSPHO1, SGMS1, SGMS2 NR5A2 4657/4885NR5A1 3689/4885SMN1; SMN2 1802/4885
US-20260144803-A1 LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF STARD3, STARD7, PHOSPHO1 NR5A2 912/4885NR5A1 167/4885SMN1; SMN2 3764/4885
US-20180000850-A1 PHOSPHOLIPID COMPOSITIONS PHOSPHO1, SGMS1, SGMS2 NR5A2 4657/4885NR5A1 3689/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.